loader
banner
Share:

Our Mission

Acellera’s mission is to accelerate the transition to rational, computerized drug discovery via simulations and machine learning.

In order to fulfill this vision, we work with our customers by becoming a key technology partner, boosting their discovery workflow with the most innovative solutions. Science, research, innovation and development are the core values of our company.

Our Background

Acellera is devoted to bringing state-of-the-art technologies to drug discovery. Founded in 2006, we were one of the first companies worldwide to leverage the use of novel accelerator processor technology (GPU) for molecular dynamics.

We developed the first online platform for drug design based on deep learning and are now leading the introduction of machine learning techniques into the drug discovery pipeline.

img
acellera-logo

2006

Acellera's foundation

2009

ACEMD released - MD on GPU

2011

Fitness of MD for Drug Discovery:
The Benzamidine -Trypsin example

2016

Introduction of HTMD: Lowering the Barrier to build, Run and analyze MD

2018

Launch of PlayMolecule - Machine Learning for Drug Design

2020

OpenMM collaboration - Chan-Zuckerberg Initiative support

2021

First private PlayMolecule instance

Today, our software ACEMD has over 700 citations, and KDeep and Deepsite are among the most cited papers in the field of ML applied to drug discovery.

img

6,404

Papers citing Acellera's founders

735

Papers citing ACEMD software

16

Years Of Experience

Careers

Computational Chemistry Scientist

We are looking for a computational scientist with experience in structure-based drug design and medicinal chemistry to join our MD services and drug discovery team. Read more and apply…

img
Newsletter

Subscribe for Newsletter